新型口服头孢菌素BMY-28100的抗菌活性比较
Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.
作者信息
Chin N X, Neu H C
出版信息
Antimicrob Agents Chemother. 1987 Mar;31(3):480-3. doi: 10.1128/AAC.31.3.480.
Abstract
BMY-28100 is a new oral cephalosporin which had in vitro activity superior to that of cephalexin and cefaclor against staphylococci, beta-hemolytic streptococcal species, and Streptococcus pneumoniae. It inhibited beta-lactamase-producing Haemophilus influenzae, Neisseria gonorrhoeae, 50% of Streptococcus faecalis isolates, Listeria monocytogenes, and 50 to 75% of Escherichia coli and Klebsiella species at less than or equal to 8 micrograms/ml, but high producers of beta-lactamase were resistant. Enterobacter, Citrobacter, Morganella, Providencia, and Pseudomonas species and Bacteroides fragilis were resistant. BMY-28100 was more stable than cefaclor against hydrolysis by beta-lactamases.
摘要
BMY - 28100是一种新型口服头孢菌素，其体外活性优于头孢氨苄和头孢克洛，对葡萄球菌、β - 溶血性链球菌和肺炎链球菌均有活性。它能抑制产β - 内酰胺酶的流感嗜血杆菌、淋病奈瑟菌、50%的粪肠球菌分离株、单核细胞增生李斯特菌以及50%至75%的大肠杆菌和克雷伯菌属，浓度小于或等于8微克/毫升，但高产β - 内酰胺酶的菌株具有耐药性。阴沟肠杆菌、柠檬酸杆菌、摩根菌属、普罗威登斯菌属、假单胞菌属和脆弱拟杆菌均耐药。BMY - 28100比头孢克洛更稳定，不易被β - 内酰胺酶水解。
相似文献
1
Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.新型口服头孢菌素BMY-28100的抗菌活性比较
Antimicrob Agents Chemother. 1987 Mar;31(3):480-3. doi: 10.1128/AAC.31.3.480.
2
Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.新型口服活性头孢菌素FR 17027的体外活性及β-内酰胺酶稳定性比较
Antimicrob Agents Chemother. 1984 Aug;26(2):174-80. doi: 10.1128/AAC.26.2.174.
3
Antimicrobial activity and beta-lactamase stability of BMY-28232, parent compound of an oral cephalosporin.
Eur J Clin Microbiol Infect Dis. 1990 Nov;9(11):841-6. doi: 10.1007/BF01967389.
4
BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.新型口服头孢菌素BMY-28100：对近7000株近期临床分离菌株的抗菌活性、与其他口服制剂的相对效价以及对产β-内酰胺酶分离菌株的活性
Diagn Microbiol Infect Dis. 1988 Jan;9(1):11-26. doi: 10.1016/0732-8893(88)90056-9.
5
Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.新型口服头孢菌素FK482的体外活性及β-内酰胺酶稳定性比较
Antimicrob Agents Chemother. 1989 Oct;33(10):1795-800. doi: 10.1128/AAC.33.10.1795.
6
The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.新型广谱β-内酰胺酶稳定头孢菌素BMY 28142的活性。
J Antimicrob Chemother. 1986 Apr;17(4):441-52. doi: 10.1093/jac/17.4.441.
7
In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.口服亚胺甲氧基氨噻唑基头孢菌素R-3746的体外活性
Antimicrob Agents Chemother. 1988 May;32(5):671-7. doi: 10.1128/AAC.32.5.671.
8
In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074).两种口服头孢菌素头孢替胺（Ro 19-5247）和头孢他美酯（Ro 15-8074）的体外活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1986 Sep;30(3):423-8. doi: 10.1128/AAC.30.3.423.
9
Comparative in vitro activity and beta-lactamase stability of RU29246, the active metabolite of HR916B.HR916B的活性代谢产物RU29246的体外活性及β-内酰胺酶稳定性比较
Eur J Clin Microbiol Infect Dis. 1992 Jul;11(7):652-9. doi: 10.1007/BF01961678.
10
In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporin.新型口服头孢菌素BMY-28100的体外和体内评价
J Antibiot (Tokyo). 1987 Aug;40(8):1175-83. doi: 10.7164/antibiotics.40.1175.
引用本文的文献
1
Redefining the management of pediatric tonsillopharyngitis with cefprozil.用头孢丙烯重新定义小儿扁桃体咽炎的治疗。
Indian J Pediatr. 2007 Dec;74(12):1105-8. doi: 10.1007/s12098-007-0206-8.
2
Penetration of cefprozil into tonsillar and adenoidal tissues.头孢丙烯在扁桃体和腺样体组织中的渗透情况。
Antimicrob Agents Chemother. 1993 May;37(5):1180-3. doi: 10.1128/AAC.37.5.1180.
3
Effects of time of administration and posture on the pharmacokinetics of cefprozil.给药时间和体位对头孢丙烯药代动力学的影响。
Clin Pharmacokinet. 1993 Sep;25(3):237-42. doi: 10.2165/00003088-199325030-00006.
4
Cefprozil versus penicillin V in treatment of streptococcal tonsillopharyngitis.头孢丙烯与青霉素V治疗链球菌性扁桃体咽炎的对比
Antimicrob Agents Chemother. 1993 Aug;37(8):1620-3. doi: 10.1128/AAC.37.8.1620.
5
Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections.头孢布烯和头孢克洛在实验性腹腔感染中高于最低抑菌浓度的最佳时间。
Antimicrob Agents Chemother. 1994 May;38(5):1112-7. doi: 10.1128/AAC.38.5.1112.
6
Comparative studies of cefprozil in the management of skin and soft-tissue infections.头孢丙烯治疗皮肤和软组织感染的对比研究。
Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):866-71. doi: 10.1007/BF02111354.
7
Comparative microbiological activity and pharmacokinetics of cefprozil.
Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):839-45. doi: 10.1007/BF02111350.
8
Penetration of cefprozil into middle ear fluid of patients with otitis media.头孢丙烯在中耳炎患者中耳液中的渗透情况。
Antimicrob Agents Chemother. 1994 Sep;38(9):2210-2. doi: 10.1128/AAC.38.9.2210.
9
Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.头孢丙烯。对其抗菌活性、药代动力学特性及治疗潜力的综述。
Drugs. 1993 Feb;45(2):295-317. doi: 10.2165/00003495-199345020-00008.
10
World-wide development of antibiotic resistance in pneumococci.肺炎球菌抗生素耐药性在全球范围内的发展。
Eur J Clin Microbiol. 1987 Aug;6(4):367-77. doi: 10.1007/BF02013089.
本文引用的文献
1
Comparison of in vitro activity of cephalexin, cephradine, and cefaclor.头孢氨苄、头孢拉定和头孢克洛的体外活性比较。
Antimicrob Agents Chemother. 1977 Mar;11(3):470-4. doi: 10.1128/AAC.11.3.470.
Zotero 插件